earnings
confidence high
sentiment positive
materiality 0.75
West Pharma Q3 net sales $804.6M (+7.7%), adjusted EPS $1.96; raises FY guidance
WEST PHARMACEUTICAL SERVICES INC
2025-Q3 EPS
reported $4.97
vs consensus $1.70
▲ beat
(+192.6%)
- Proprietary Products HVP Components net sales $390M, +16.3% YoY, driven by GLP-1 products and HVP conversion.
- Full-year 2025 net sales guidance raised to $3.060-3.070B; adjusted EPS guidance raised to $7.06-7.11.
- Q4 2025 guidance: net sales $790-800M, adjusted diluted EPS $1.81-1.86.
- Free cash flow nine months $293.9M, +53.7% YoY; repurchased 552,593 shares for $134.0M.